News | August 08, 2024
Balaji Amines Q4 FY25 revenue stood at Rs. 393 Cr
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Revolutionary technology will further boost OneSource’s scientific services offerings
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Subscribe To Our Newsletter & Stay Updated
